Concepedia

Sanjiv S. Agarwala

SS

Statistics

Publications

121

Citations

23.7K

H-Index

55

Active since

1968

Affiliations

St. Luke's University Health Network(Current)

UPMC Hillman Cancer Center

University of Pittsburgh

The University of Texas MD Anderson Cancer Center

Temple University

Sanjiv S. Agarwala is an author at St. Luke's University Health Network specializing in oncology, medicine, and metastatic melanoma treatment.

Publications per year

1968–2024

121

Publications

121

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3.2K citations · Full text

Medicine, Oncology, Cancer Pharmacology +11

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

Michael A. Postow, Jason Chesney, Anna C. Pavlick et al. · New England Journal of Medicine · 2015 · 2.8K citations · Full text

Life Sciences, Immunology, Oncology +17

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

Robert H.I. Andtbacka, Howard L. Kaufman, Frances A. Collichio et al. · Journal of Clinical Oncology · 2015 · 2.6K citations · Full text

Medicine, Immunology, Oncology +17

Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer

Marshall R. Posner, Diáne Hershock, C. Blajman et al. · New England Journal of Medicine · 2007 · 1.7K citations · Full text

Medicine, Oncology, Chemotherapy +8

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

Antoni Ribas, Igor Puzanov, Reinhard Dummer et al. · The Lancet Oncology · 2015 · 1.6K citations · Full text

Medicine, Clinical Sciences, Oncology +15

1–5 of 121